We are submitting this application in response to RFA-DK-08-015 """"""""Chronic Kidney Disease Biomarker Discovery and Validation Consortium."""""""" We propose to utilize the ongoing NIDDK-sponsored Chronic Renal Insufficiency Cohort (CRIC) as a Validation Site. We propose late-phase validation studies of established biomarkers of kidney injury and eady-phase validation studies of novel biomarkers identified by discovery activities within the Consortium. In both cases, we propose to use banked urine and plasma specimens from CRIC, a large NIDDK-sponsored longitudinal cohort study of over 3900 individuals with chronic kidney disease designed to identify new risk factors for chronic kidney disease progression. Specifically, we will determine levels of established sensitive biomarkers of kidney injury (urinary neutrophil- gelatinase-associated lipocalin, kidney injury molecule-1, liver fatty acid-binding protein, interleukin-18, cystatin C;and plasma plasminogen activator inhibitor-1) in CRIC. We hypothesize that higher levels of these biomarkers of kidney injury will be associated with more severe chronic kidney disease. We will also determine if absolute levels of kidney injury biomarkers or if changes in their levels correlate with subsequent loss of renal function (defined as progression to end stage renal disease or doubling of serum creatinine, a FDA-accepted endpoint for chronic kidney disease). We hypothesize that these markers of kidney injury will correlate with disease progression, and in fact will be independent predictors of future loss of renal function even after known clinical risk factors have been taken into consideration. Finally, we will use biosamples from CRIC to perform early phase validation studies for biomarkers discovered by members of the Chronic Kidney Disease Biomarker Consortium (including biomarkers discovered through our currently funded R21 CRIC ancillary proteomic study). Validating these biomarkers in an independent group of CRIC enrollees will serve as a paradigm for our approach to early validation studies in CRIC. If we are selected to be a member of the Chronic Kidney Disease Biomarker Consortium, CRIC will make available 2.5 mL of plasma and 5 mL of urine to the Consortium for biomarker validation efforts. The large and diverse CRIC cohort-with its detailed characterization of enrollees over time, excellent participant retention, and availability of carefully collected biospecimens-presents a unique and powerful platform to validate biomarkers of chronic kidney disease progression.

Public Health Relevance

Chronic kidney disease is a major and growing health problem in the United States. Better markers to identify patients with chronic kidney disease who are at high risk of disease complications (such as progression of disease) are desperately needed. We propose here to test the predictive value of biomarkers for chronic kidney disease progression in patient samples from the ongoing NIDDK-sponsored Chronic Renal Insufficiency Cohort (CRIC), a longitudinal study with more than 3900 participants.

National Institute of Health (NIH)
National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK)
Research Project--Cooperative Agreements (U01)
Project #
Application #
Study Section
Special Emphasis Panel (ZDK1-GRB-S (O1))
Program Officer
Kimmel, Paul
Project Start
Project End
Budget Start
Budget End
Support Year
Fiscal Year
Total Cost
Indirect Cost
University of California San Francisco
Internal Medicine/Medicine
Schools of Medicine
San Francisco
United States
Zip Code
Wheelock, Kevin M; Cai, Jian; Looker, Helen C et al. (2017) Plasma bradykinin and early diabetic nephropathy lesions in type 1 diabetes mellitus. PLoS One 12:e0180964
Xie, Dawei; Yang, Wei; Jepson, Christopher et al. (2017) Statistical Methods for Modeling Time-Updated Exposures in Cohort Studies of Chronic Kidney Disease. Clin J Am Soc Nephrol 12:1892-1899
Roy, Jason; Shou, Haochang; Xie, Dawei et al. (2017) Statistical Methods for Cohort Studies of CKD: Prediction Modeling. Clin J Am Soc Nephrol 12:1010-1017
Liu, Kathleen D; Humphreys, Benjamin D; Endre, Zoltan H (2017) The ten barriers for translation of animal data on AKI to the clinical setting. Intensive Care Med 43:898-900
Inker, Lesley A; Coresh, Josef; Sang, Yingying et al. (2017) Filtration Markers as Predictors of ESRD and Mortality: Individual Participant Data Meta-Analysis. Clin J Am Soc Nephrol 12:69-78
Park, Meyeon; Hsu, Chi-Yuan; Go, Alan S et al. (2017) Urine Kidney Injury Biomarkers and Risks of Cardiovascular Disease Events and All-Cause Death: The CRIC Study. Clin J Am Soc Nephrol 12:761-771
Hsu, Jesse Yenchih; Roy, Jason A; Xie, Dawei et al. (2017) Statistical Methods for Cohort Studies of CKD: Survival Analysis in the Setting of Competing Risks. Clin J Am Soc Nephrol 12:1181-1189
Hsu, Chi-Yuan; Xie, Dawei; Waikar, Sushrut S et al. (2017) Urine biomarkers of tubular injury do not improve on the clinical model predicting chronic kidney disease progression. Kidney Int 91:196-203
Waikar, Sushrut S; Sabbisetti, Venkata; Ärnlöv, Johan et al. (2016) Relationship of proximal tubular injury to chronic kidney disease as assessed by urinary kidney injury molecule-1 in five cohort studies. Nephrol Dial Transplant 31:1460-70
Foster, Meredith C; Coresh, Josef; Hsu, Chi-Yuan et al. (2016) Serum ?-Trace Protein and ?2-Microglobulin as Predictors of ESRD, Mortality, and Cardiovascular Disease in Adults With CKD in the Chronic Renal Insufficiency Cohort (CRIC) Study. Am J Kidney Dis 68:68-76

Showing the most recent 10 out of 24 publications